In the BioHarmony Drug Report Database

"Preview" Icon

Pasireotide

Signifor Lar, Signifor (pasireotide) is a protein pharmaceutical. Pasireotide was first approved as Signifor Lar on 2012-04-24. It is used to treat cushing syndrome in the USA. It has been approved in Europe to treat acromegaly and pituitary acth hypersecretion. The pharmaceutical is active against somatostatin receptor type 3, somatostatin receptor type 1, somatostatin receptor type 2, and somatostatin receptor type 5. Signifor’s patents are valid until 2028-05-23 (FDA).

 

Trade Name

 

Signifor
 

Common Name

 

pasireotide
 

ChEMBL ID

 

CHEMBL3039583
 

Indication

 

acromegaly, cushing syndrome, pituitary acth hypersecretion
 

Drug Class

 

Peptides: inhibition of growth hormone release

Image (chem structure or protein)

Pasireotide structure rendering